NCT03179917 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03179917
Title	Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Memorial Sloan Kettering Cancer Center
Indications	Hodgkin's lymphoma
Therapies	Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA

Filter rows:

Showing 1 to 9 of 9 entries

Facility	City	State	Zip	Country	Details
Abramson Cancer Center at University of Pennsylvania (Data Collection Only)	Philadelphia	Pennsylvania	19104-4283	United States	Details
Memorial Sloan Kettering at Basking Ridge	Basking Ridge	New Jersey	07920	United States	Details
Memorial Sloan Kettering Bergen	Montvale	New Jersey	07645	United States	Details
Memorial Sloan Kettering Cancer Center	New York	New York	10065	United States	Details
Memorial Sloan Kettering Commack	Commack	New York	11725	United States	Details
Memorial Sloan Kettering Monmouth	Middletown	New Jersey	07748	United States	Details
Memorial Sloan Kettering Nassau	Uniondale	New York	11553	United States	Details
Memorial Sloan Kettering Westchester	Harrison	New York	10604	United States	Details
University of Miami	Miami	Florida	33136	United States	Details

Showing 1 to 9 of 9 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT03179917Clinical Trial Detail